Bicara Therapeutics (BCAX) Other Non-Current Liabilities (2023)

Bicara Therapeutics' (BCAX) quarterly Other Non-Current Liabilities came in at $17000.0 in Q4 2023.

Bicara Therapeutics (BCAX) Other Non-Current Liabilities (2023) Analysis & Trends

Bicara Therapeutics' Other Non-Current Liabilities history runs 1 years deep, the most recent figure standing at $17000.0 for Q4 2023.

On a quarterly basis, Other Non-Current Liabilities changed N/A year-over-year to $17000.0 in Q4 2023; TTM through Dec 2023 was $17000.0, a N/A change from a year earlier, with the FY2023 full-year figure at $17000.0, changed N/A from the prior year.
Other Non-Current Liabilities was little changed at $17000.0 in Q4 2023 per BCAX's latest filing.
Across five years, Other Non-Current Liabilities topped out at $17000.0 in Q4 2023 and bottomed at $17000.0 in Q4 2023.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	67,072.09 Bn	67,072.09 Bn	-
2	Nanobiotix	1,894.61 Bn	1,894.55 Bn	-
3	Akari Therapeutics	1,014.18 Bn	1,014.18 Bn	-
4	BeOne Medicines	471.64 Bn	466.85 Bn	1.35 Bn
5	Vertex Pharmaceuticals	121.72 Bn	114.47 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	68.28 Bn	59.52 Bn	3.31 Bn
7	Belite Bio	61.40 Bn	61.40 Bn	-
8	Argenx Se	56.94 Bn	56.94 Bn	1.18 Bn
9	Revolution Medicines	37.37 Bn	37.37 Bn	-
10	Bicara Therapeutics	1.64 Bn	1.64 Bn	-

Download Data

Date	Value
Dec 31, 2023	17,000.00